Lion Point Capital, LP Regenxbio Inc. Transaction History
Lion Point Capital, LP
- $157 Million
- Q1 2024
A detailed history of Lion Point Capital, LP transactions in Regenxbio Inc. stock. As of the latest transaction made, Lion Point Capital, LP holds 32,500 shares of RGNX stock, worth $354,250. This represents 0.44% of its overall portfolio holdings.
Number of Shares
32,500Holding current value
$354,250% of portfolio
0.44%Shares
1 transactions
Others Institutions Holding RGNX
# of Institutions
193Shares Held
42.1MCall Options Held
80.6KPut Options Held
55.2K-
Black Rock Inc. New York, NY7.6MShares$82.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.88MShares$53.2 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.55MShares$49.6 Million3.78% of portfolio
-
Jpmorgan Chase & CO New York, NY3.72MShares$40.6 Million0.01% of portfolio
-
State Street Corp Boston, MA3.12MShares$34 Million0.0% of portfolio
About REGENXBIO Inc.
- Ticker RGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,230,000
- Market Cap $471M
- Description
- REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...